TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors combine to determine variation in disease progression. A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN . Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n =1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The rs58542926 minor allele of transmembrane 6 superfamily member 2 (TM6SF2) is also reportedly associated with MASLD and sometimes MASH (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, the splice variant rs72613567 in the Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17B13) gene has been identified as protective against MASH, with HSD17B13 potentially contributing to MASH fibrosis by promoting pyrimidine catabolism (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e · Cited by 2,772
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Purcell, S., Cherny, S. S., & Sham, P. C. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.1.149 · Cited by 2,057
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citation
Cited by
Items 301–400 of 623
Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals
Phipps, M. M., & Wattacheril, J. J. (2019) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101119 · Cited by 28
Leslie, J., Krishnamurthy, K. A., Gopalsamy, I. K., Inácio, P., Huch, M., Gallage, S., Oakley, F., & Vacca, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01162-9 · Cited by 30
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
Stevenson, H. L., & Utay, N. S. (2016) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-016-0038-5 · Cited by 23
van der Meer, D., Gurholt, T. P., Sønderby, I. E., Shadrin, A. A., Hindley, G., Rahman, Z., de Lange, A. G., Frei, O., Leinhard, O. D., Linge, J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04237-4 · Cited by 31
Xu, M., Sun, Y., Dai, X., Zhan, J., Long, T., Xiong, M., Li, H., Kuang, Q., Tang, T., Qin, Y., et al. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.12.007 · Cited by 23
Mederacke, Y., Kirstein, M. M., Großhennig, A., Marhenke, S., Metzler, F., Manns, M. P., Vogel, A., & Mederacke, I. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15722 · Cited by 23
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
Koenig, A. B., Tan, A., Abdelaal, H., Monge, F., Younossi, Z. M., & Goodman, Z. D. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18059 · Cited by 29
Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
Rabiu, L., Zhang, P., Afolabi, L. O., Saliu, M. A., Dabai, S. M., Suleiman, R. B., Gidado, K. I., Ige, M. A., Ibrahim, A., Zhang, G., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02157-0 · Cited by 26
“Particularly the splice variant rs72613567 of the HSD17B13 gene has been identified as a protective factor against MASH [28–30].”
Zhang, Y., Xie, M., Wen, J., Liang, C., Song, Q., Liu, W., Liu, Y., Song, Y., Lau, H. C.-H., Cheung, A. H. K., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-333154 · Cited by 29
Self-citationLiver fibrogenesis: un update on established and emerging basic concepts
Novo, E., Bocca, C., Foglia, B., Protopapa, F., Maggiora, M., Parola, M., & Cannito, S. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108445 · Cited by 26
“Up-regulation of miR-155 detected in experimental ALD has been related to a reduced hepatocyte expression of PPARα and increased expression of genes involved in lipid metabolism and uptake, including low-density lipoprotein receptor (LDLR), fatty acid binding protein 4 (FABP4) and Acetyl-CoA carboxylase 1 (ACC1) [158].”
BackgroundInfluentialBanini, B. A., & Sanyal, A. J. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2020.11.001 · Cited by 21
Caring for children with NAFLD and navigating their care into adulthood
Mencin, A., Loomba, R. S., & Lavine, J. E. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.146 · Cited by 23
Gentilucci, U. V., Dell’Unto, C., Vincentis, A. D., Baiocchini, A., Monache, M. D., Cecere, R., Pellicelli, A. M., Giannelli, V., Carotti, S., Galati, G., et al. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/7564835 · Cited by 25
“has been associated with steatosis and fibrosis in patients with NAFLD [24, 25].”
BackgroundAdvancing precision medicine in metabolic dysfunction-associated steatotic liver disease
Priego-Parra, B. A., Gallego‐Durán, R., Román-Calleja, B. M., Velasco, J. A. V.-R., Romero‐Gómez, M., & Gracia‐Sancho, J. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.006 · Cited by 28
Ma, J., Ma, Y., Wan, X., Li, J., Zhang, Y., Liu, J., & Gao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1639064 · Cited by 26
Mechanisms and therapeutic insights into MASH-associated fibrosis
Zhu, Y., & Cai, B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.09.004 · Cited by 32
Non-alcoholic Fatty Liver Disease in Children
Muzurović, E. M., Pοlyzos, S. A., Mikhailidis, D. P., Borozan, S., Novosel, D., Cmiljanić, O., Kadić, N., & Mantzoros, C. S. (2022) · Current Vascular Pharmacology · doi:10.2174/1570161121666221118155136 · Cited by 25
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i2.92791 · Cited by 24
“TM6SF2 inhibition is associated with reduced secretion of TG-rich lipoproteins and increased cellular TG concentration and lipid droplet content, while TM6SF2 overexpression reduced steatosis[43,45,46].”
InfluentialPractical approach to non‐alcoholic fatty liver disease in patients with diabetes
Tai, F. W. D., Syn, W., & Alazawi, W. (2015) · Diabetic Medicine · doi:10.1111/dme.12725 · Cited by 21
Käräjämäki, A. J., Hukkanen, J., Kauma, H., Kesäniemi, Y. A., & Ukkola, O. H. (2019) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2019.1700428 · Cited by 23
“TM6SF2 is disturbed by the rs58542926 variant, making it more unstable, affecting its function in lipid metabolism and resulting in intrahepatic fat accumulation [16,20,21], and possibly even more progressive NAFLD stages [11,17].”
BackgroundGenetic risk factors associated with NAFLD
Kim, D. Y., & Park, J. Y. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.96 · Cited by 20
“57 × 10), independently of PNPLA3 I148M([30]).”
InfluentialGenetic and non-genetic drivers of histological progression and regression in MASLD
Gómez, E. V., Yates, K. P., Kleiner, D. E., Behling, C. A., Cummings, O. W., Wilson, L., Liang, T., Jarasvaraparn, C., Loomba, R., Schwimmer, J. B., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.013 · Cited by 29
Sunami, Y., Rebelo, A., & Kleeff, J. H. (2021) · Cancers · doi:10.3390/cancers13174391 · Cited by 22
“In univariate but not multivariate analysis, homozygote carriage of the TM6SF2 rs58542926 C > T polymorphism is associated with an increased risk of NAFLD-HCC (Table 1) [68].”
BackgroundZou, H., Ge, Y., Lei, Q., Ung, C. O. L., Ruan, Z., Lai, Y., Yao, D., & Hu, H. (2022) · Hepatology International · doi:10.1007/s12072-021-10286-4 · Cited by 20
What’s new in non-alcoholic fatty liver disease?
Spiers, J., Brindley, J. H., Li, W., & Alazawi, W. (2022) · Frontline Gastroenterology · doi:10.1136/flgastro-2022-102122 · Cited by 26
Seko, Y., Yamaguchi, K., Shima, T., Iwaki, M., Takahashi, H., Kawanaka, M., Tanaka, S., Mitsumoto, Y., Yoneda, M., Nakajima, A., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.02.031 · Cited by 23
Omics‐derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases
Fujiwara, N., Qian, T., Koneru, B., & Hoshida, Y. (2020) · Hepatology Research · doi:10.1111/hepr.13506 · Cited by 20
Kim, H. Y., Baik, S. J., Lee, H. A., Lee, B. K., Lee, H. S., Kim, T. H., & Yoo, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-74659-9 · Cited by 21
Pharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver Disease
Lorbek, G., Urlep, Ž., & Rozman, D. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0047 · Cited by 21
Anstee, Q. M., Liu, Y., Day, C. P., & Reeves, H. L. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.028 · Cited by 21
“Journal of Hepatology 2015, 62(4), 982-983.”
Self-citationZhang, X., Chang, K., Yu, J. Q., & Loomba, R. S. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023430 · Cited by 21
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Sayıner, M., Lam, B. P., Golabi, P., & Younossi, Z. M. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818811508 · Cited by 20
Identification of genes in hepatocellular carcinoma induced by non-alcoholic fatty liver disease
Cai, C., Song, X., & Yu, C. (2020) · Cancer Biomarkers · doi:10.3233/cbm-190169 · Cited by 20
“Previous studies have confirmed the genetic polymorphisms of patatin-like phospholipase domain containing 3 (PNPLA3) [11] and transmembrane 6 superfamily member 2 (TM6SF2) [12] are associated with a higher risk of HCC in patients with NAFLD.”
BackgroundClinical and Molecular Prediction of Hepatocellular Carcinoma Risk
Kubota, N., Fujiwara, N., & Hoshida, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123843 · Cited by 21
Liver Steatosis: A Marker of Metabolic Risk in Children
Neri, C. R., Scapaticci, S., Chiarelli, F., & Giannini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094822 · Cited by 25
Rahdan, F., Saberi, A., Saraygord‐Afshari, N., Hadizadeh, M., Arjmand, T. F., Ghanbari, E., Dianat‐Moghadam, H., & Alizadeh, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39489 · Cited by 18
“Additionally, variants of member 2 of superfamily 6 (TM6SF2) are linked to NAFLD and are correlated with increased steatosis, cirrhosis, and NASH [60,61].”
BackgroundPetta, S., Maida, M. F., Grimaudo, S., Pipitone, R. M., Macaluso, F. S., Cabibi, D., Cammà, C., Marco, V. D., Sferrazza, S., & Craxı̀, A. (2015) · Liver International · doi:10.1111/liv.12918 · Cited by 18
“In the analysis, the TM6SF2 E172K variant was coded in a dominant genetic model because of its relatively low allele frequency (19,20).”
BackgroundResultIs Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?
Goossens, N., & Hoshida, Y. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.006 · Cited by 18
The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant
Zhang, X., Liu, S., Dong, Q., Xin, Y., & Xuan, S. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2018.00022 · Cited by 20
“TM6SF2 E167K variant in HCC HCC is the sixth most common cancer and the third cause of cancer-related morbidity and mortality worldwide.47 The main risk factors of HCC include NASH, alcohol intake, ingestion of the fungal metabolite aflatoxin B1, and hepatitis B virus and HCV infections.48–50 Increasing evidence has s…”
BackgroundInfluentialEuropean paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale
Mann, J. P., Vreugdenhil, A. C. E., Socha, P., Jańczyk, W., Baumann, U., Rajwal, S. R., Casswall, T., Marcus, C., van Mourik, I., O’Rahilly, S., et al. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.11.003 · Cited by 19
Self-citationNonalcoholic fatty liver disease and cardiovascular disease phenotypes
Bisaccia, G., Ricci, F., Mantini, C., Tana, C., Romani, G. L., Schiavone, C., & Gallina, S. (2020) · SAGE Open Medicine · doi:10.1177/2050312120933804 · Cited by 21
Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
Qi, Y., Fan, L., Ran, D., Xu, J., Wang, Y., Wu, J., & Zhang, Z. (2021) · Journal of Oncology · doi:10.1155/2021/7764817 · Cited by 22
“TM6SF2rs 58542926 mutation was closely related to NAFLD, age, body mass index (BMI), and T2DM [31].”
BackgroundFactors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
Parameswaran, M., Hasan, H. A., Sadeque, J., Jhaveri, S., Avanthika, C., Arisoyin, A. E., Dhanani, M., & Rath, S. M. (2021) · Cureus · doi:10.7759/cureus.20776 · Cited by 22
“TM6SF2 rs58542926 VLDL secretion Increases incidence and progression [92-93]”
BackgroundSessa, A. D., Sanseverino, N. C. S., Simone, R. F. D., Marrapodi, M. M., Cirillo, G., Umano, G. R., Guarino, S., Papparella, A., del Giudice, E. M., & Marzuillo, P. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02041-3 · Cited by 17
Tian, Y., & Wang, B. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16330 · Cited by 21
“SURP and G-patch domain containing 1 ( SUGP1 ) is ubiquitously expressed in a wide range of tissues and located closely to TM6SF2 on human chromosome 19.”
BackgroundKaplan, D. E., Teerlink, C. C., Schwantes-An, T.-H. L., Norden‐Krichmar, T. M., DuVall, S. L., Morgan, T. R. M., Tsao, P. S., Voight, B. F., Lynch, J. A., Vujković, M., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000487 · Cited by 21
“…disease and chronic hepatitis C. [17,18,21] In MASLD, PNPLA3 rs738409 has been associated with more severe inflammation, advanced fibrosis, [16,19,20,22 – 24,26 , 28] to cirrhosis, [6,15, 24, 27] HCC , [20, 25 – 27 ] and liver-related death [ As with all VA studies, the preponderance of men…”
BackgroundXue, W.-Y., Zhang, L. R., Liu, C., Gao, Y., Li, S., Huai, Z., Dai, J., & Wang, Y. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2032661 · Cited by 19
“independent association between this mutation and HCC [43].”
BackgroundResultInfluentialBalcar, L., Scheiner, B., Urheu, M., Weinberger, P., Paternostro, R., Simbrunner, B., Semmler, G., Willheim, C., Pinter, M., Ferenci, P., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.02.012 · Cited by 19
Mitten, E. K., & Baffy, G. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.37 · Cited by 17
Lee, J., Kim, J., Kim, J. O., & Kwon, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04291-4 · Cited by 18
“In particular, phospholipase domain-containing 3 (PNPLA3) [9, 10] and transmembrane 6 superfamily member 2 (TM6SF2) [10] are well known and replicated genetic markers that associated with hepatic fibrosis/cirrhosis [11, 12], hepatitis [13], and hepatocellular carcinoma [14, 15].”
BackgroundThe Association between Pediatric NAFLD and Common Genetic Variants
Umano, G. R., Martino, M., & Santoro, N. (2017) · Children · doi:10.3390/children4060049 · Cited by 17
“Several studies also report an association with liver damage, both inflammation and fibrosis, in adults [38,39] and children [37,40].”
BackgroundPasta, A., Borro, P., Cremonini, A. L., Formisano, E., Tozzi, G., Cecchi, S., Fresa, R., Labanca, S., Sheijani, A. D., Sukkar, S. G., et al. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.820 · Cited by 15
Type 2 diabetes sex-specific effects associated with E167K coding variant in TM6SF2
Fan, Y., Wolford, B. N., Lu, H., Liang, W., Sun, J., Zhou, W., Rom, O., Mahajan, A., Surakka, I. L., Graham, S. E., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103196 · Cited by 17
“In contrast, carriers of the minor allele (encoding lysine at codon 167) have an increased risk for NAFLD, steatosis, fibrosis, and cirrhosis (Kozlitina et al., 2014; Liu et al., 2014; Mahdessian et al., 2014; Sookoian et al., 2015).”
BackgroundAller, R., Fernández‐Rodríguez, C., Iacono, O. L., Bañares, R., Abad, J., Carrión, J. A., García‐Monzón, C., Caballería, J., Berenguer, M., Rodríguez‐Perálvarez, M., et al. (2018) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2018.05.013 · Cited by 52
Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study
Viitasalo, A., Pihlajamäki, J., Paananen, J., Atalay, M., Lindi, V., & Lakka, T. A. (2016) · Pediatric Research · doi:10.1038/pr.2016.3 · Cited by 16
A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry
Schwantes-An, T.-H. L., Whitfield, J. B., Aithal, G. P., Atkinson, S. R., Bataller, R. A., Botwin, G., Chalasani, N., Cordell, H. J., Daly, A. K., Darlay, R., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000431 · Cited by 22
“[12] The score identified a 3-fold difference in risk (for cirrhosis among high-risk drinkers) between people in the top and bottom quintiles, which was also recently confirmed in an independent cohort.”
Self-citationSeko, Y., Yamaguchi, K., Shima, T., Iwaki, M., Takahashi, H., Kawanaka, M., Tanaka, S., Mitsumoto, Y., Yoneda, M., Nakajima, A., et al. (2024) · Liver International · doi:10.1111/liv.16124 · Cited by 16
The additive effects of theTM6SF2 E167KandPNPLA3 I148Mpolymorphisms on lipid metabolism
Chen, L., Du, S.-X., Lu, L., Lin, Z., Jin, W., Hu, D., Jiang, X., Xin, Y., & Xuan, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18474 · Cited by 19
Whole‐Exome Sequencing Study of Extreme Phenotypes of NAFLD
Kleinstein, S. E., Rein, M., Abdelmalek, M. F., Guy, C. D., Goldstein, D. B., Diehl, A. M., & Moylan, C. A. (2018) · Hepatology Communications · doi:10.1002/hep4.1227 · Cited by 15
Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities
Du, X., DeForest, N., & Majithia, A. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.777075 · Cited by 19
“and further supported by associations between the variant and cT1 values (84) and histologically ascertained NAS and SAF scores (91), indicating that TM6SF2 rs58542926 is implicated in NASH in addition to NAFL.”
BackgroundAdvances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
Riccio, S., Melone, R., Vitulano, C., Guida, P., Maddaluno, I., Guarino, S., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2022) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v11.i3.221 · Cited by 15
Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease
Jiang, Z. G., Tapper, E. B., Kim, M.-S., Connelly, M. A., Krawczyk, S. A., Yee, E. U., Herman, M. A., Mukamal, K. J., & Lai, M. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000816 · Cited by 16
“Num [n (%)] 48 (28) 56 (32) 31 (19) 15 (9) 13 (7) 5 (3) 2 (1) Conventional lipid profile* (mg/dL) Triglyceride 205±162 210±102 185±121 177±85 142±65 208±156 558 Total cholesterol 192±56 197±34 202±47 187±53 168±45 168±42 195 LDL-C 108±45 117±29 118±40 104±51 97±37 85±53 98 HDL-C 48±17 43±11 47±16 48±10 42±13 48±9 26 C…”
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.036 · Cited by 15
Qiu, Y., Laguna, J. C., Alegret, M., & Vilà, L. (2026) · Nutrients · doi:10.3390/nu18040679 · Cited by 16
“…lysine at position 167 of the rs58542926 SNP leads to loss of function of the hepatic VLDL secretory pathway, which induces elevation of hepatic triglyceride levels and thus increases susceptibility to liver injury [98,99], but reduces cardiovascular risk by decreasing circulating lipids [100,101].”
Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis
Buchynskyi, M., Oksenych, V., Kamyshna, I. I., Vari, S. G., & Kamyshnyi, O. (2023) · Viruses · doi:10.3390/v15081724 · Cited by 12
The genetic landscape of neuro-related proteins in human plasma
Repetto, L., Chen, J., Yang, Z., Zhai, R., Timmers, P. R. H. J., Feng, X., Li, T., Yao, Y., Maslov, D. E., Timoshchuk, A. N., et al. (2024) · Nature Human Behaviour · doi:10.1038/s41562-024-01963-z · Cited by 20
“Neurocan core protein (NCAN) was found to be genetically associated with high cholesterol, and thus also cholesterol-lowering substitutes such as the use of Flora Pro-Activ or Benecol, since it was used more frequently than the other products, revealing its colocalized genetic associations at the cis -pQTL of NCAN (Fi…”
InfluentialFatty Liver Disease and Hepatocellular Carcinoma: The Pathologist’s View
TINIAKOS, D. G., Maurício, J., & Reeves, H. L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-98788-0_4 · Cited by 16
Self-citationInterplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
Ramadan, M. S., Russo, V., Nigro, G., Durante‐Mangoni, E., & Zampino, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081569 · Cited by 15
“In another study, Liu et al. demonstrated an association between NAFLD and the stage of hepatic fibrosis with TM6SF2 allele, independent of PNPLA3 [136].”
BackgroundInfluentialGovaere, O., Petersen, S. K., Martínez-López, N., Wouters, J., Haele, M. V., Mancina, R. M., Jamialahmadi, O., Bilkei‐Gorzo, O., Lassen, P. B., Darlay, R., et al. (2020) · Journal of Hepatology · doi:10.1016/s0168-8278(20)30598-5 · Cited by 14
Self-citationAssessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events
Saki, S., Saki, N., Poustchi, H., & Malekzadeh, R. (2020) · Middle East Journal of Digestive Diseases · doi:10.34172/mejdd.2020.166 · Cited by 17
Kocas‐Kilicarslan, Z. N., Cetin, Z., Faccioli, L. A. P., Motomura, T., Amirneni, S., Díaz‐Aragon, R., Florentino, R. M., Sun, Y., Plá-Palacín, I., Xia, M., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.011 · Cited by 13
“38 The variant has been associated with increased risk for MASH 28,39 and MASH-associated fi brosis/cirrhosis.”
BackgroundThe Intestinal Thread of Fate: How the Microbiota Shapes the Story of Liver Disease
Acierno, C., Nevola, R., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Caturano, A. (2025) · Livers · doi:10.3390/livers5020017 · Cited by 16
“Although this polymorphism is associated with lower total cholesterol and LDL levels, it paradoxically increases the risk of advanced fibrosis and MASLD-HCC, highlighting the dual impact of genetic alterations on lipid metabolism and liver disease progression [35,36].”
Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using “Good-Fit” Genome-Editing Tools
Kim, U., Kim, N., & Shin, H. Y. (2020) · Cells · doi:10.3390/cells9122572 · Cited by 13
“Gene Function Variant Phenotype of Genetic Variant Reference PNPLA3 TG lipase rs738409 C > G(I148M) Increased hepatic fat content, high risk of hepatic steatosis, fibrosis, and HCC [11–13] TM6SF2 Involved in very low-density lipoprotein (VLDL) secretion and hepatic TG metabolism rs58542926 C > T (E167K) Elevated hepat…”
BackgroundInfluentialHepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge
de Mattos, Â. Z., Debes, J. D., Dhanasekaran, R., Benhammou, J. N., Arrese, M. A., Patrício, A. L. V., Zilio, A. C., & de Mattos, Â. A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.1107 · Cited by 14
Kim, K., Kang, K., Sheol, H., Shin, J., Sim, Y., Yang, T., Hwang, J.-W., & Lee, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031042 · Cited by 13
“Some genetic predispositions, including PNPLA3 and TM6SF2, are known to be associated with NAFLD [4,5].”
BackgroundKorkiakoski, A., Käräjämäki, A. J., Ronkainen, J., AUVINEN, J. P., Hannuksela, J., Kesäniemi, Y. A., & Ukkola, O. H. (2022) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2022.2059698 · Cited by 15
Nonalcoholic Fatty Liver Disease and Fibrosis Progression: The Good, the Bad, and the Unknown
Harrison, S. A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.024 · Cited by 14
Urzua, A. M., Gabriel Mezzano, P., Brahm, J., Poníachik, J., Miranda, J., Cáceres, D., Carreño, L. E., & Venegas, M. (2017) · Hepatitis Monthly · doi:10.5812/hepatmon.44365 · Cited by 12
“Similarly, studies on patients with NAFLD and without HCV infection also report very low prevalence of homozygous patients with unfavorable T allele (9, 10).”
BackgroundInfluentialMa, Y., Chen, G., Yi, J., Li, Q., Tan, Z., Fan, W., Luo, X., He, Z., Si, Z., & Li, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.895593 · Cited by 14
Lan, T., & Tacke, F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156015 · Cited by 16
Samji, N. S., Verma, R., Keri, K., Singal, A. K., Ahmed, A., Rinella, M. E., Bernstein, D., Abdelmalek, M. F., & Satapathy, S. K. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05716-1 · Cited by 12
Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
Singh, S. P., Anirvan, P., Khandelwal, R., & Satapathy, S. K. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00174 · Cited by 12
Sabotta, C. M., Kwan, S., Petty, L. E., Below, J. E., Joon, A. Y., Wei, P., Fisher‐Hoch, S. P., McCormick, J. B., & Beretta, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.995488 · Cited by 12
“The T allele of variant rs58542926 in TM6SF2 is also known to be strongly associated with NAFLD and risk for advanced liver fibrosis (Liu et al., 2014).”
BackgroundNanizawa, E., Tamaki, Y., Sono, R., Miyashita, R., Hayashi, Y., Kanbe, A., Ito, H., & Ishikawa, T. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100736 · Cited by 14
“Furthermore, the influence of HFD intake in other background of mice should be examined to evaluate the relevance of genetic factors to the development of NASH is reported in human study [41,42].”
BackgroundAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P. J., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/186387 · Cited by 12
Data-driven cluster analysis identifies distinct types of cardiovascular-kidney-metabolic syndrome
Yang, M., Su, C., Chang, X., Wang, G., & Liu, J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf708 · Cited by 16
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma
Kodama, T., & Takehara, T. (2024) · Seminars in Liver Disease · doi:10.1055/a-2289-2298 · Cited by 16
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction
Ciardullo, S., & Perseghin, G. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.39 · Cited by 15
Huang, H. Y. R., Vitali, C., Zhang, D., Hand, N. J., Phillips, M. C., Creasy, K. T., Scorletti, E., Park, J., Schneider, K. M., Rader, D. J., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101243 · Cited by 15
Clinical features and management issues of NAFLD-related HCC: what we know so far
Pugliese, N., Alfarone, L., Arcari, I., Giugliano, S., Parigi, T. L., Rescigno, M., Lleò, A., & Aghemo, A. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2162503 · Cited by 13
“Moreover, the transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 gene polymorphism, which promotes breakdown of the protein modulating lipoprotein transfer, and the membrane bound 0-acyltransferase domain containing 7 (MBOAT7) rs641738 variant, which hampers the phospholipid remodeling pathway, have been associa…”
BackgroundRecent advances in understanding/management of non-alcoholic steatohepatitis
Pacana, T., & Sanyal, A. J. (2015) · F1000Prime Reports · doi:10.12703/p7-28 · Cited by 14
Sagnelli, C., Merli, M., Uberti‐Foppa, C., Hasson, H., Grandone, A., Cirillo, G., Salpietro, S., Minichini, C., Starace, M., Messina, E., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i38.8509 · Cited by 11
Grove, J. I., Austin, M. J., Tibble, J. A., Aithal, G. P., & Verma, S. (2016) · PubMed · doi:10.5604/16652681.1193726 · Cited by 12
Self-citationFunctional annotation of sixty-five type-2 diabetes risk SNPs and its application in risk prediction
Wu, Y., Jing, R., Dong, Y., Kuang, Q., Li, Y., Huang, Z., Gan, W., Xue, Y., Li, M., & Li, M. (2017) · Scientific Reports · doi:10.1038/srep43709 · Cited by 15
Do, D. N., Schenkel, F. S., Miglior, F., Zhao, X., & Ibeagha-Awemu, E. M. (2020) · Animal Genetics · doi:10.1111/age.12901 · Cited by 21
Faccioli, L. A. P., Cetin, Z., Kocas‐Kilicarslan, Z. N., Ortiz, K., Sun, Y., Hu, Z., Kurihara, T., Tafaleng, E. N., Florentino, R. M., Wang, Z., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713406 · Cited by 11
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 12
Self-citationCommon Pathogenetic Pathways of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Giannopoulos, C., Tzima, I. G., Tentolouris, N., & Vasileiadis, I. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230216112032 · Cited by 14
Farrell, A., Ryan, M. C., & Howell, J. A. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2019.019 · Cited by 10
Metadata
- Authors
- Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., Donaldson, P., Aithal, G. P., Francque, S., Van Gaal, L., Clement, K., Ratziu, V., Dufour, J.-F., Day, C. P., Daly, A. K., & Anstee, Q. M.
- Affiliations
- Newcastle University (GB)
- Addenbrooke's Hospital (GB)
- University Hospital of Bern (CH)
- Inserm (FR)
- Nottingham University Hospitals NHS Trust (GB)
- Antwerp University Hospital (BE)
- Pitié-Salpêtrière Hospital (FR)
- Corresponding author
- Anstee, Quentin M.
- ORCID
- Venue
- Nature Communications
- Published
- 2014-06-30
- Volume
- 5
- Issue
- 1
- Pages
- 4309-4309
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4279183
- OpenAlex
- W2038831349
- Cited by
- 623
- References
- 45
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 50 · 2023: 51 · 2022: 56 · 2021: 61 · 2020: 82 · 2019: 49 · 2018: 50 · 2017: 45 · 2016: 54 · 2015: 50 · 2014: 11
- FWCI
- 40.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Open Access CRIS of the University of Bern
- Funders
- National Institute for Health and Care Research (FP7/2007–2013)
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 241762)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- TM6SF2, rs58542926, non-alcoholic fatty liver disease, liver fibrosis, liver cirrhosis, non-synonymous polymorphisms, genetic association, hepatic triglyceride content, neurocan, chromosome 19, steatohepatitis, PNPLA3, disease progression
- MeSH terms
- Adult, Aged, Alleles, Female, Genotype, Heterozygote, Humans, Liver, Liver Cirrhosis, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Cohort Studies, Disease Progression, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Lectins, C-Type, Neurocan, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.